algoWatt and Italeaf sign the Recovery Agreement with the Sole Representative of the Bondholders
algoWatt and Italeaf sign the Recovery Agreement with the Sole Representative of the Bondholders
algoWatt S.p.A., GreenTech Solutions Company listed on the MTA market of Borsa Italiana, announces that, today, Mr. Stefano Neri, as Chairman of the Board of Directors and legal representative of algoWatt, duly authorised by virtue of the resolution adopted by the Board of Directors on 21 June 2021, and Ms. Monica Federici, as Managing Director and legal representative of the parent company Italeaf S.p.A., duly authorized by a resolution of the Board of Directors on 21 June, and Mr. Marzio Molinari, as sole representative of the subscribers of the bond called "Algowatt Tv Eur6m+1.5 Dc27 Amort Eur", listed on the ExtraMOT PRO market, organized and managed by Borsa Italiana S.p.A., duly authorised by virtue of the resolution passed by the Bondholders' Meeting on 30 April 2021 and in compliance with the provisions of the pactum de non petendo signed inter partes on 22 December 2020, on the other hand, signed the Recovery Agreement pursuant to Article 67, paragraph 3, letter d) of the Bankruptcy Law, consistent with the provisions of the Plan for the Recovery of the debt exposure of algoWatt and Italeaf and the rebalancing of their financial situation pursuant to Article 67, paragraph 3, letter d) Bankruptcy Law approved yesterday, 21 June 2021, by the Boards of Directors of the Companies.
This fulfilment is part of the activities resolved by the Board of Directors of the Company on 21 June 2021 and represents the first important step in the implementation of the commitments undertaken therein, aimed at achieving the completion of the Recvoery Agreement by the scheduled deadline of 9 July 2021. The effects of the signed Agreement shall be retroactive, in any case, to today's date of June 22, 2021 (the "Effective Date").
algoWatt is assisted by R&S Advisory S.r.l. as financial advisor and by Studio Legale Fallanca Scicolone & Partners, in the person of Marco Scicolone, lawyer, for legal advisory activities. Marzio Molinari of Studio Russo De Rosa Associati is the sole representative of the bondholders.
This press release is available on the Company's website www.algowatt.com
algoWatt (ALW), greentech solutions company, designs, develops and integrates solutions for energy and natural resource management in a sustainable and socially responsible manner. The Company provides management and control systems that integrate devices, networks, software and services with a clear sector focus: digital energy and utilities, smart cities & enterprises and green mobility. algoWatt is the result of the merger of TerniEnergia, a leading company in the renewable energy and environmental industry, and Softeco, an ICT solutions provider with over 40 years of experience for customers operating in the energy, industry and transport sectors. The company, with more than 200 employees located in 7 locations in Italy and investments in research and innovation for more than 12% of turnover, operates with an efficient corporate organization, focused on the following markets: Green Energy Utility: renewable energy, digital energy, smart grids; Green Enterprise&City: IoT, data analysis, energy efficiency, building and process automation; Green Mobility: electric, shared and on demand. Different markets, a single focus: sustainability. algoWatt is listed on the Mercato Telematico Azionario (MTA) of Borsa Italiana S.p.A..
For further info:
| InvestorRelations | PressOffice | Investor&MediaRelations |
| algoWatt SpA | algoWatt SpA | Domenico Gentile, Pietro Autelitano |
| Filippo Calisti (CFO) | Federico Zacaglioni | Via Bigli, 19 - 20121 Milano |
| Tel. +39 0744 7581 | Tel. +39 0744 7581 | Tel. +39 02 4547 3883/4 |
| filippo.calisti@algowatt.com | Mobile +39 340 5822368 | ir@irtop.com |
| federico.zacaglioni@algowatt.com | ufficiostampa@irtop.com |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Boyden Welcomes Healthcare & Life Sciences Expert Stephen Irish as Managing Partner, Japan4.8.2021 20:00:00 CEST | Press release
Long-term specialist in senior-level recruitment in Japan and Asia/Pacific joins Boyden as head of the Japan office and member of Boyden’s global healthcare & life sciences practice TOKYO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome Stephen Irish as Managing Partner and head of Boyden Japan. Based in Tokyo, Irish joins Boyden’s global healthcare & life sciences practice, leading senior level searches for clients in Japan and Asia/Pacific, as well as those headquartered outside the region. “Japan is a unique market, and requires specialist knowledge and understanding of the cultural nuances at the individual, organisational and government level,” commented Stephen Irish, Managing Partner, Boyden Japan. “Having worked with Japanese companies throughout my career, I am delighted to bring this experience into a collaborative, international environment with Boyden. For clients
Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:41:41 CEST | Press release
4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo
Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:23:58 CEST | Press release
4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo
Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting4.8.2021 15:00:00 CEST | Press release
Press release, Helsinki, 4 August 2021 at 4 PM(EEST) Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it will be exhibiting during the annual meeting of the Texas Association of Neurological Surgeons this week, August 5-8, 2021 at the Hyatt Regency Lost Pines Resort & Spa in Lost Pines, Texas. This meeting continues to be a significant opportunity for Nexstim to engage current and prospective users of the Nexstim system. Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a
ProMIS Neurosciences Issues Chairman’s Memorandum4.8.2021 13:30:00 CEST | Press release
Notes and comments after the first AAIC meeting in the era of approved disease-modifying therapies for Alzheimer’s Disease TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting. “We are in a new era in the fight against Alzheimer’s, ALS, and other neurodegenerative diseases,” stated Eugene Williams, Executive Chairman of ProMIS Neurosciences. “ProMIS and many others have predicted this development and we believe that the Alzheimer’s community will look back on 2021 as a turning point, just as 2010 was a turnin
Aspo Plc will publish its Half year financial report on August 11, 20214.8.2021 12:00:00 CEST | Press release
Aspo Plc Press Release August 4, 2021 at 1 p.m. Aspo Plc will publish its Half year financial report on August 11, 2021 Aspo Plc will publish its Half year financial report for January–June 2021 on Wednesday, August 11, 2021 at approximately 9:30 a.m. EEST. The press conference for analysts, investors and media will be held on Wednesday, August 11, 2021 at 2 p.m. The Half year financial report will be presented by CEO Aki Ojanen. The press conference will be held in Finnish and it can be followed at https://aspo.videosync.fi/2021-q2-results, or by calling +358 9 817 10310 (12219443#) 5 to 10 minutes before the beginning of the press conference. The recording of the event will be available on the company’s website later on the same day. Presentation material will be available at www.aspo.com before the event. Aspo Plc Aki Ojanen CEO For further information, please contact: Keijo Keränen, Group Treasurer, +358 400 955 821, keijo.keranen@aspo.com DISTRIBUTION: Key media www.aspo.com Aspo
Cortus Energy: Sista dag för handel med betalda tecknade units (BTU) och omvandling till aktier och teckningsoptioner av serie TO8 och TO94.8.2021 09:46:34 CEST | Pressemelding
PRESSMEDDELANDE Stockholm, den 4 augusti 2021 Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) har som tidigare kommunicerats genomfört en övertecknad företrädesemission av units om cirka 64,8 MSEK ("Företrädesemissionen"). Företrädesemissionen är nu registrerad hos Bolagsverket ochsista dag för handel med BTU är fredagenden 6augusti 2021. Avstämningsdag för omvandlingen är den 10augusti 2021, varefter BTU kommer att omvandlas till aktier och teckningsoptioner av serie TO8 och TO9. Aktier och teckningsoptioner som tecknades i Företrädesemissionen förväntas vara tillgängliga på tecknarens depå/vp-konto den 12 augusti 2021. Första handelsdag för teckningsoptionerna i serie TO8 och TO9 förväntas vara den 13 augusti 2021. Teckningsoptioner av serie TO8 Teckning av aktier med stöd av teckningsoptioner av serie TO8 sker under perioden från och med den 16 november 2021 till och med den 29 november 2021. Varje teckningsoption av serie TO8 ger rätt att teckna en (1) ny aktie i Bolaget mot kon